ETrade Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

ETrade Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-27,559	Closed	-$1.65M	–	845
2018 Q2	$1.65M	Sell	27,559 -1,082	-4%	-$56.1K	0.05%	214
2018 Q1	$1.31M	Buy	28,641 +1,587	+6%	+$66.2K	0.04%	257
2017 Q4	$1.08M	Buy	27,054 +504	+2%	+$19.9K	0.03%	331
2017 Q3	$1.06M	Sell	26,550 -3,275	-11%	-$142K	0.04%	314
2017 Q2	$1.28M	Sell	29,825 -5,115	-15%	-$182K	0.05%	212
2017 Q1	$1.09M	Sell	34,940 -4,307	-11%	-$115K	0.05%	236
2016 Q4	$991K	Sell	39,247 -6,858	-15%	-$153K	0.05%	240
2016 Q3	$1.14M	Sell	46,105 -6,739	-13%	-$153K	0.06%	195
2016 Q2	$1.08M	Buy	52,844 +1,264	+2%	+$22.4K	0.06%	199
2016 Q1	$787K	Buy	+51,580	New	+$673K	0.04%	255

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

ETrade Capital Management's SUPN Position: Q3 2018 in Review

ETrade Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 27,559 shares — an estimated $1.65M sold.

ETrade Capital Management first reported a position in SUPN in Q1 2016 and held it in 10 quarters. The position peaked at $1.65M in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

ETrade Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
ETrade Capital Management sold 27,559 Supernus Pharmaceuticals shares in Q3 2018, an estimated $1.65M.
ETrade Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 10 quarters.
ETrade Capital Management's Supernus Pharmaceuticals position peaked at $1.65M in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on ETrade Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.